This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03347396\], and BIVV009-04/EFC16216 \[NCT03347422\]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.
Кой може да участва
Inclusion Criteria:
1. Patient aged ≥18 years
2. Patient able to understand the purpose of the study and who (or whose legally authorized representative) provided signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations
3. Patient with a diagnosis of CAD or CAS as per Investigator judgment based on the diagnosis criteria listed in study protocol
Exclusion Criteria:
1. Patient with mixed warm and cold autoimmune hemolytic anemia, or warm autoimmune hemolytic anemia
2. Patient actively participating in a CAD or CAS interventional clinical trial. After a patient completes participation in said trial, he/she may be eligible for enrollment in this registry.
Интервенции
Sutimlimab
DRUG
Места на провеждане
68
Австрия (2)
Investigational Site Number : 3101
Salzburg
Investigational Site Number : 3102
Vienna
Франция (16)
Investigational Site Number : 3222
Amiens
Investigational Site Number : 3214
Angers
Investigational Site Number : 3204
Cesson-Sévigné
Investigational Site Number : 3211
Chalon-sur-Saône
Investigational Site Number : 3206
Corbeil-Essonnes
Investigational Site Number : 3201
Créteil
Investigational Site Number : 3219
Dijon
Investigational Site Number : 3221
Epagny-Metz-Tessy
Investigational Site Number : 3217
Paris
Investigational Site Number : 3213
Pau
Investigational Site Number : 3203
Pessac
Investigational Site Number : 3216
Poitiers
Investigational Site Number : 3202
Quimper
Investigational Site Number : 3220
Rennes
Investigational Site Number : 3205
Saint-Priest-en-Jarez
Investigational Site Number : 3218
Toulouse
Германия (3)
Investigational Site Number : 3301
Essen
Investigational Site Number : 3306
Hanover
Investigational Site Number : 3302
Landshut
Италия (9)
Investigational Site Number : 3413
Brescia , Lombardy
Investigational Site Number : 3410
Campobasso
Investigational Site Number : 3403
Novara
Investigational Site Number : 3411
Palermo
Investigational Site Number : 3415
Pavia
Investigational Site Number : 3412
Ravenna
Investigational Site Number : 3402
Reggio Calabria
Investigational Site Number : 3404
Roma
Investigational Site Number : 3405
Terni
Япония (2)
Investigational Site Number : 2203
Fukushima , Fukushima
Investigational Site Number : 2204
Himeji-shi , Hyōgo
Испания (2)
Investigational Site Number : 3701
Barcelona , Barcelona [Barcelona]
Investigational Site Number : 3712
Madrid
Великобритания (15)
Investigational Site Number : 3623
Airdrie , North Lanarkshire
Investigational Site Number : 3618
Birmingham
Investigational Site Number : 3617
Carlisle , Cumbria
Investigational Site Number : 3608
Gillingham , Kent
Investigational Site Number : 3620
Harrow
Investigational Site Number : 3612
Leeds
Investigational Site Number : 3607
Liverpool
Investigational Site Number : 3605
London , London, City of
Investigational Site Number : 3621
London
Investigational Site Number : 3613
Middlesbrough , North Yorkshire
Investigational Site Number : 3601
Newcastle upon Tyne , North Tyneside
Investigational Site Number : 3611
Oxford , Oxfordshire
Investigational Site Number : 3602
Salford , Manchester
Investigational Site Number : 3606
Taunton , Somerset
Investigational Site Number : 3603
Truro , Cornwall
САЩ (19)
Piedmont Cancer Institute, P.C Site Number : 1226
Atlanta , Georgia
University of Alabama at Birmingham Site Number : 1230
Birmingham , Alabama
Cleveland Clinic Foundation Site Number : 1207
Cleveland , Ohio
The Ohio State University Site Number : 1236
Columbus , Ohio
Henry Ford Hospital Site Number : 1232
Detroit , Michigan
Brody School of Medicine at East Carolina University Site Number : 1203
Greenville , North Carolina
UT Medical Center Cancer Institute Site Number : 1237
Knoxville , Tennessee
Northwell Health-Monter Cancer Center-North Shore University Hospital and Steven and Alexandra Cohen Children's Medical Center of New York (Schneider Children's Hospital)-North Shore Long Island Jewis Site Number : 1231
Lake Success , New York
Hematology Oncology Associates, PC Site Number : 1211
Medford , Oregon
Center for Blood Disorders Site Number : 1214
New York , New York
University of Pittsburgh Medical Center-UPMC Hillman Cancer Center Site Number : 1210
Pittsburgh , Pennsylvania
SLO Oncology and Hematology Site Number : 1235
San Luis Obispo , California
Mission Hope Medical Oncology Site Number : 1241
Santa Maria , California
University of Washingtion Seattle Cancer Care Alliance Site Number : 1238
Seattle , Washington
Siouxland Regional Cancer Center dba June E. Nylen Cancer Center Site Number : 1220
Sioux City , Iowa
Orchard Heathcare Research Inc. Site Number : 1202
Skokie , Illinois
SUNY Upstate Medical University Site Number : 1221
Syracuse , New York
MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center Site Number : 1208
БГ
EN